You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Metolazone - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for metolazone and what is the scope of patent protection?

Metolazone is the generic ingredient in four branded drugs marketed by Gd Searle Llc, Alembic, Ani Pharms, Bayshore Pharms Llc, Innogenix, Mylan, Ne Rx Pharma, Renata, Roxane, Rubicon, Sandoz, Watson Labs, Chartwell Molecular, and I3 Pharms, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for metolazone. Seventeen suppliers are listed for this compound.

Summary for metolazone

US Patents:	0
Tradenames:	4
Applicants:	14
NDAs:	15
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	17
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	22
Patent Applications:	6,291
Formulation / Manufacturing:	see details
Drug Prices:	Drug price trends for metolazone
What excipients (inactive ingredients) are in metolazone?	metolazone excipients list
DailyMed Link:	metolazone at DailyMed

See drug prices for metolazone

Drug Sales Revenue Trends for metolazone

See drug sales revenues for metolazone

Recent Clinical Trials for metolazone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rambam Health Care Campus	Phase 4
St George's, University of London	Phase 3
NHS Greater Glasgow and Clyde	Phase 3

See all metolazone clinical trials

Pharmacology for metolazone

Drug Class	Thiazide-like Diuretic
Physiological Effect	Increased Diuresis

Medical Subject Heading (MeSH) Categories for metolazone

Antihypertensive Agents
Diuretics
Sodium Chloride Symporter Inhibitors

US Patents and Regulatory Information for metolazone

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	METOLAZONE	metolazone	TABLET;ORAL	075543-002	Mar 1, 2004		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Roxane	METOLAZONE	metolazone	TABLET;ORAL	076482-002	Apr 29, 2004		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
I3 Pharms	ZAROXOLYN	metolazone	TABLET;ORAL	017386-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for metolazone

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chartwell Molecular	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.